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Non-small cell lung cancer (NSCLC) shows a particular aggressive behaviour. Tumour
associated macrophages (TAMs) play an important role in tumour growth and progression
and CC ligand 2 (CCL2)/CCR2 axis is markedly involved in their recruitment in the tumour
mass from the circulation.
The aim of this study was to determine the plasma levels of CCL2 and the expression of
CCR2 in the peripheral blood mononuclear cells (PBMCs) of 18 smokers with NSCLC, eight
healthy smokers and nine non-smokers. Then, we investigated CCL2 levels in the
supernatants of unstimulated and LPS-stimulated PBMC cultures of the same groups of
patients.
CCL2 levels in plasma and supernatants of PBMC cultures were determined by ELISA. CCR2
expression in PBMC cytospins was assessed by immunocytochemistry.
CCL2 plasma levels and CCR2 expression by PBMCs were similar in patients with NSCLC,
healthy smokers and non-smokers. In the supernatants of unstimulated PBMC cultures,
CCL2 content was not different between the three groups of subjects. Supernatants of LPS-
stimulated PBMCs of NSCLC patients showed a higher content of CCL2 as compared to
supernatants of non-smokers (po0.005). CCL2 content increased 28.5-fold vs baseline
production in the group of NSCLC patients, 15-fold in healthy smokers and 13-fold in the
group of non-smokers.Elsevier Ltd. All rights reserved.
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CCL2 in NSCLC 1739In conclusion, after LPS stimulation, PBMCs of patients with NSCLC release higher levels of
CCL2 as compared to those of non-smokers, supporting the hypothesis of a CCL2
involvement in NSCLC biology.
& 2007 Elsevier Ltd. All rights reserved.Introduction
The overall 5-year survival rate of patients with non-small
cell lung cancer (NSCLC) is less than 15%.1 The complex
interaction between tumour cells and the host immune
network contributes to determine the aggressive behaviour
of lung cancer.2
Cells belonging to the monocyte-macrophages lineage are
a major component of the leucocyte infiltrate of neoplasms
and tumour associated macrophages (TAMs) are recognized
to play an important role in tumour growth and progression.3
It is generally accepted that most TAMs are derived from
peripheral blood monocytes recruited into the tumour mass
from the circulation.3,4 Recruitment of circulating mono-
cytes into the tumour mass is directed by chemokines.
Chemokines are small heparin-binding proteins playing a
crucial role in directing the movement of mononuclear cells
throughout the body, engendering the adaptive immune
response and contributing to the pathogenesis of a variety of
diseases.5 They are divided into four families on the basis of
differences in structure and function. Monocyte chemotac-
tic protein-1 is the most thoroughly characterized member
of the CC chemokine family and it has been termed as CC
ligand 2 (CCL2) in the new classification system.5,6 It mainly
acts through the CCR2 receptor which is expressed by
monocytes, immature dendritic cells and memory T cells.5
CCL2 stimulates chemotaxis of peripheral blood mono-
cytes and of memory T cells.5,7 It also induces calcium flux,
respiratory burst activity, adhesion molecule and proin-
flammatory cytokine expression in monocytes.8,9 Many
evidences support the hypothesis that CCL2 regulates
tumour growth and progression by recruiting inflammatory
cells into the tumour mass, enhancing the cytotoxic activity
in monocytes and natural killer cells and modulating the
angiogenesis and the immune response against the tumour
through the regulation of mediator release by mono-
cytes.10–15
Different tumour cells express CCL2 both in vivo and in
vitro, including NSCLC cells.2,10–12,15,16 CCL2 is also ex-
pressed by TAMs and activated human peripheral blood
monocytes.17–19
The aims of this study were to determine the plasma
levels of CCL2 and the expression of CCR2 in peripheral
blood mononuclear cells (PBMCs) of smokers with NSCLC,
healthy smokers and non-smokers, and to investigate CCL2
levels in the supernatants of unstimulated and LPS-stimu-
lated PBMC culture of the same groups of patients.
Materials and methods
Study population
The study group comprised 18 patients with primary NSCLC,
and 17 control subjects (nine smokers and eight non-smokers). All subjects underwent an interview and data
collected included age, gender, occupation, and smoking
history. Routine pulmonary function tests were performed
and baseline FEV1 and FEV1/FVC were recorded. Lung
cancer patients had not received chemotherapy or radiation
before surgery. In these patients, histopathological diagnosis
was done in samples obtained at biopsy (10 of the 18)
or at surgery (8 of the 18). The pathologic tumour stage
(p stage) was determined according to the revised TNM
classification.20
Blood samples and PBMC isolation
Peripheral blood samples from patients and controls were
collected into Vacutainers sterile tubes (BD, Franklin Lakes,
NJ, USA) containing 2500 U Liquemins (La Roche A.G,
Wyhlen, Germany). Lung cancer patients were bleeded the
day of biopsy or surgery. Samples were diluted 1:1 with
RPMI-1640 medium and layered on Hystopaque-1077s
(Sigma, Milan, Italy). Samples were centrifuged three times
and each time the interface band of PBMCs was collected
and resuspended in cold PBS (phosphate buffered saline).
After the last centrifugation, cells were resuspended in
RPMI-1640 medium (BE 12-167F, BiowhittakerTM, Cambrex
Bioscience, Verviers, Belgium) containing 10% heat-inacti-
vated FCS (CHA 2111D Celbio, Milan, Italy), 1% L-glutammin
(BE 17-605E, BiowhittakerTM, Cambrex Bioscience, Verviers,
Belgium), and 0.25% antibiotics (penicillin–streptomycin
mixture, 17-602E BiowhittakerTM, Cambrex Bioscience,
Verviers, Belgium). Plasma samples were collected and
stored at 20 1C.
Isolation of adherent cells
Isolated PBMCs from subjects were cultured 1 106 cells/ml
medium in 24 well tissue culture plates. Cells were
incubated for 1 h 30min at 37 1C in humified atmosphere,
and non-adherent cells were removed by washing with PBS.
Monocytes were incubated in RPMI-1640 with or without
10 mg/ml LPS (2654, Sigma, Milan, Italy). After 24, 48 or 72 h
supernatants were withdrawn, centrifuged and stored at
20 1C.
On the basis of preliminary experiments, we decided to
assess CCL2 levels in the supernatants of PBMCs incubated
for 48 h with or without LPS.
CCL2 quantification
CCL2 levels in the plasma and supernatants were deter-
mined by ELISA (CYT20, Chemicon international Inc.,
Temecula, CA, USA). The assay was performed according
to the manufacturer’s instructions. The minimal detectable
level was 13.1 pg/ml.
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Table 1 Demographic and clinical data.
Smokers
with lung
cancer
(n ¼ 18)
Healthy
smokers
(n ¼ 9)
Non-
smokers
(n ¼ 8)
Sex (male/female) 18/0 8/1 7/1
Age (yrs) 6572 6073 5772
Pack-years 5276** 3774** 0.170.1
FEV1 (% pred.) 7477*
,*** 9774 10277
FEV1/FVC (%) 6975*** 8774 8073
Type of tumour (no. of subjects)
Adenocarcinoma 7
Squamous cell
carcinoma
8
Undifferentiated 3
TNM stage (no. of subjects)
I 8
II 2
III 3
IV 5
Data are presented as mean7standard error of the mean;
*po0.05 and **po0.001 vs non-smokers; ***po 0.05 vs
healthy smokers. FEV1 and FEV1/FVC were measured in 15
patients with lung cancer.
D. Miotto et al.1740Immunocytochemistry
After PBMC separation, 4 106 cells were withdrawn and
cytospinned at a concentration of 1 106 cells/ml. Differ-
ential cell count was performed after Diff-Quick staining of
slides. Immunocytochemistry was performed by using the
method of the streptavidin biotin complex conjugated with
alkaline phosphatase. Sections were incubated with a goat
anti-human polyclonal antibody anti-CCR2 (sc-6228, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) 1:50 in TMS
(tris maleate saponin solution). Slides were subsequently
incubated with rabbit anti-goat biotinylated immunoglobu-
lins (E466, Dako Ltd., Glostrup, Denmark) and with
streptavidin biotin complex conjugated to alkaline phos-
phatase (StreptABComplex/AP, K391, Dako Ltd., Glostrup,
Denmark). Immunoreactivity was visualized with fast red
(K699; Dako Ltd.). Sections were counterstained with
haematoxylin and mounted in Glycergel (C563; Dako Ltd.).
Cell count was performed using an Olympus BX41 light
microscope (Olympus Optical Co., Hamburg, Germany).
For each slide, at least 400 monocytes were counted in at
least 10 randomly selected fields. Monocytes were identi-
fied by means of morphologic criteria and results were
expressed as percentage of CCR2+ve monocytes/total
number of monocytes. Fourteen cytopsins of blood mono-
nuclear cells of patients with NSCLC, six of healthy smokers
and eight of non-smokers had a satisfactory quality to allow
the determination of the CCR2+ve mononuclear cells
percentage.Statistical analysis
Analysis of variance (ANOVA) followed by unpaired t-test for
clinical data and the non-parametric Kruskall–Wallis test
followed by the Mann–Whitney U test for histological data
were used to determine differences between groups. The
chemokine content in unstimulated and LPS-stimulated cell
culture supernatants of the same groups of subjects was
compared by the Wilcoxon signed rank test.Results
Subjects
Patient’s characteristics are summarized in Table 1. All
healthy smokers were current smokers except one who quit
smoking 2 years before entering into the study. In the group
of non-smokers, one subject was an ex-smoker from 25 years
(0.6 pack-years) whereas the remaining seven were life long
non-smokers. The mean age was similar in the three groups
of subjects. The two groups of smokers were similar with
regard to number of pack-years. Smokers with lung cancer
had a lower FEV1 (% predicted) and a lower FEV1/FVC ratio
(%) than healthy smokers (po0.05). Their FEV1 was also
lower as compared to non-smokers (po0.05). Histological
diagnosis revealed that eight patients had squamous cell
carcinoma (44%), seven had adenocarcinoma (39%) and
three had undifferentiated NSCLC (17%). Eight patients
(44%) were classified as stage I disease, and the remaining 10
(56%) as stages II, III and IV disease (late stage).CCL2 and CCR2 quantification
The CCL2 content in plasma samples was similar in smokers
with lung cancer, healthy smokers and non-smokers [median
(interquartile range): 44.0 (25.9–69.2) vs 63.6 (18.8–77.6) vs
16.6 (11.8–33.4) pg/ml, respectively].
Similarly, the CCR2 expression was comparable in PBMC
cytospins of smokers with lung cancer, healthy smokers and
non-smokers [median (interquartile range): 44.7%
(27.8–56.0) vs 35.9% (24.8–39.0) vs 31.7% (27.5–41.8),
respectively].
In the supernatants of unstimulated PBMC cultures, the
CCL2 content was not different among the three groups
of subjects (Fig. 1A). Conversely, supernatants of LPS-
stimulated PBMC cultures of smokers with lung cancer
showed a higher content of CCL2 than those of non-smokers
[median (interquartile range): 2023.4 (1008.9–2906.3) vs
660.0 (276.6–741.1) pg/ml respectively, po0.005]. On the
other hand, no significant differences were found with
healthy smokers [2023.4 (1008.9–2906.3) vs 1212.5
(480.5–1691.0) pg/ml, respectively] (Fig. 1B).
In the supernatants of smokers with lung cancer, LPS
stimulation produced a 28.5-fold increase in the CCL2
production compared to unstimulated PBMC cultures
[(2023.4 (1008.9–2906.3) vs 70.9 (36.9–168.9) pg/ml, re-
spectively, po0.005] (Fig. 2). In the supernatants of healthy
smokers, LPS produced a 15-fold increase [1212.5
(480.5–1691.0) vs 82.3 (13.8–243.7) pg/ml, respectively,
po0.05]. Finally, in the group of non-smokers, a 13-fold
increase was observed [660.0 (276.6–741.0) vs 49.0
(24.2–114.4) pg/ml, respectively, po0.05] (Fig. 2).
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Figure 1 Individual values of MCP-1 levels in the supernatants
of: (A) unstimulated and (B) LPS-stimulated PBMC cells cultures
of smokers with non-small cell lung cancer (NSCLC), healthy
smokers (S) and non-smokers (NS). Horizontal bar represents
median values. CCL2 levels were measured by ELISA. NSCLC:
n ¼ 13; S: n ¼ 7; NS: n ¼ 8.
CCL2 in NSCLC 1741The CCL2 content in plasma was similar in patients with
stage I disease as compared to patients with late stage
disease [34.1 (20.6–64.3) vs 48.2 (30.3–69.4) pg/ml, respec-
tively]. Similarly, the CCR2 expression was not different in
PBMC cytospins of patients with stage I disease as compared
to patients with late stage disease [42.9 (38.4–57.3) vs 44.7
(27.2–52.0) pg/ml, respectively].Discussion
In the present study, similar levels of CCL2 in plasma of
smokers with NSCLC, healthy smokers and non-smokers were
found. Similarly, the percentage of CCR2+ve monocytes was
not different in PBMC cytospins of the three studied groups.
CCL2 content in plasma and CCR-2 expression in PBMC
cytospins were similar in patients with early stage lung
cancer as compared to those with late stage lung cancer.
CCL2 is believed to be involved in the recruitment of
circulating monocytes to the tumour site.2,11,17,21,22 Indeed,
CCL2 levels in breast cancer homogenates and CCL2 mRNA in
gastric carcinoma and esophageal squamous cell carcinoma
correlate with TAMs accumulation in the tumours.17,21,22
Arenberg et al.2 have shown that the level of CCL2 in NSCLC
homogenates was higher than in normal lung tissue and
correlated with TAMs infiltration.We observed similar CCL2 plasma levels in patients with
NSCLC compared to controls. However, our findings do not
exclude a role of CCL2/CCR2 axis in the recruitment of
monocytes to the lung tumour, since it is likely that the CCL2
plasma levels do not exactly mirror the chemokine produc-
tion in lung cancer tissue.
The CCR2 is the only known CCL2 receptor and it is
expressed by monocytes. Recently, two functional subsets of
murine blood monocytes have been identified and it has
been suggested that only the subset corresponding to the
human monocyte population known as CD14+CD62L+CCR2+
bears the CCR2 and it is actively recruited to inflamed
tissues.23
Although CCR2 binds to other chemokines, the CCL2/CCR2
axis has unique effects on mononuclear cell migration and it
is likely an important regulator in inflammatory diseases. In
murine models of atherosclerosis and in experimental
allergic encephalomyelitis, the CCR2 deficiency reduced
macrophage recruitment to the site of disease and the
severity of disease itself.24 CCR2 expression has been found
on tumour infiltrating leukocytes in ovarian, nasopharyngeal
and esophageal squamous cell carcinomas, supporting its
involvement in the process of inflammatory cells recruit-
ment to the cancer site.22,25,26
Our finding of a similar percentage of CCR2+ve mono-
nuclear cells in the PBMC cytospins of patients with NSCLC,
healthy smokers and healthy controls does not rule out the
possibility that CCR2 has a key role in the regulation of the
process of macrophage accumulation to the tumour site. In
fact, Katschke et al.27 have demonstrated a differential
expression of chemokine receptors on peripheral blood,
synovial fluid and synovial tissue monocytes/macrophages in
rheumatoid arthritis. Patients with rheumatoid arthritis
showed a similar CCR2 expression in PBMCs, but a lower
percentage of CCR2+ve monocytes in the synovial fluid
compared to normal subjects. The authors concluded that,
in rheumatoid arthritis, CCR2 is mainly involved in the tissue
retention of recruited macrophages rather than in monocyte
recruitment from the circulation.27
Further studies are necessary to clarify the possible
differential roles of CCR2 expression by monocytes/macro-
phages in NSCLC.
The absence of difference between early and late stage
NSCLC with regard to CCL2 plasma levels and PBMC CCR2
expression may result from a mismatch in the compartments
of blood and lung cancer tissue. Other explanations include
the possibility that the current study was underpowered to
demonstrate significant differences in patients with differ-
ent tumour stages.
The major finding of our study is that LPS-stimulated
PBMC cultures of patients with NSCLC produced higher levels
of CCL2 than PBMC cultures of non-smokers. Moreover, after
LPS stimulation, the CCL2 increase vs baseline production
was greater in patients with NSCLC as compared to controls.
Taken together, these data would suggest that peripheral
monocytes of patients with NSCLC exhibit a greater response
to inflammatory stimuli in terms of CCL2 production.
Therefore, once recruited to the tumour site, this monocyte
population might contribute to enhance the local levels of
CCL2 release.
Many evidences suggest that chemokines behave more
than attractants, due to their pleiotropic effects that
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Figure 2 LPS-stimulated release of MCP-1 in the supernatants of patients with non-small cell lung cancer (NSCLC), healthy smokers
and non-smokers compared to the release in unstimulated supernatants. PBMC cell cultures were stimulated with 10 mg/ml LPS for
48 h. CCL2 levels were measured by ELISA. NSCLC: n ¼ 13; S: n ¼ 7; NS: n ¼ 8.
D. Miotto et al.1742impact the cancer pathobiology in a way that depends on
the particular setting in which they are expressed.24 Animal
models and in vitro studies indicate that CCL2 can enhance
macrophage cytolitic activity against tumour cells, stimu-
lates NK cells cytotoxic activity and suppresses systemic
spread of human lung adenocarcinoma cells by a NK cell-
mediated mechanism.13,24,28 On the other hand, CCL2 can
induce angiogenesis. Indeed, the local expression of CCL2
correlates with the levels of potent angiogenic factors
[thymidine phosphorilase (TP), vascular endothelial growth
factor (VEGF), tumour necrosis factor (TNF)-a, interleukin
(IL)-8] in human breast cancer extracts and CCL2+ve
samples of carcinoma of the esophagus show higher TP
expression and microvessels density than those CCL2
negative.17,29 Finally, in human prostate cancer and in
carcinoma of the esophagus, CCL2 would promote tumour
cell proliferation, while in pancreatic cancer, circulating
CCL2 levels inversely correlate with the tumour proliferative
activity.10,12,29
The functional significance of CCL2 expression in human
NCSLC remains to be clarified. However, the finding of an
increased chemokine expression at tumour tissue level
compared to normal lung and the correlation between
CCL2 expression and macrophage infiltration suggest that
CCL2 may be involved in the NSCLC biology.2 Our findings are
coherent with these results and indicate that, a local
recruitment of monocytes, prone to release high levels of
CCL2, would contribute to modify the tumour microenviron-
ment, thus modulating inflammatory cell activation and
chemotaxis, angiogenesis and, eventually, tumour cell
proliferation.
In conclusion, the current authors have found that, after
LPS stimulation, PBMCs of patients with NSCLC release
higher levels of CCL2 as compared to those of non-smokers.These results suggest the CCL2 involvement in NSCLC
biology. Future investigations will be needed to better
elucidate the functional role of CCL2 in NSCLC growth and
progression.
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